Pneumococcal conjugate vaccines (PCV) may reduce nasopharyngeal carriage (NPC) of Streptococcus pneumoniae vaccine strains (VT), but serotype replacement with non-vaccine strains (NVT) has been reported. Bacterial NPC after PHiD-CV vaccination was assessed in the second year of life. Open descriptive study of NPC reported for 414 subjects vaccinated at 3-5 and 12-15 months of age with PHiD-CV with or without prophylactic paracetamol (PP) compared to 336 age-matched PCV-naïve controls. Carriage was assessed prior to and 1, 3, 7 and 12 months after PHiD-CV booster or MenACWY-TT control vaccination at 12-15 months of age. At each visit, carriage of VT was reduced by 22-35% in PHiD-CV recipients. Vaccine efficacy across all visits was 21.7% [95% CI 2.6; 37.0] (26.8% carriage in the PHiD-CV group versus 34.2% in controls). Carriage rates of NVT tended to be higher in PHiD-CV recipients. Pre-booster, these findings were more pronounced when PP had not been administered. No substantial effect of PHiD-CV vaccination was observed on NPC of other bacterial pathogens including non-typeable Haemophilus influenzae. Primary and booster vaccination with PHiD-CV reduced NPC of VT in the second year of life and tended to slightly increase that of NVT in line with previous experience with the 7-valent PCV.

Charles University Prague Faculty of Medicine in Hradec Kralove Department of Clinical Microbiology Hradec Kralove Czech Republic

Department of Epidemiology Military Medical Academy Hradec Kralove Czech Republic

Faculty of Military Health Sciences University of Defence Hradec Kralove Czech Republic

Global Vaccine Development GlaxoSmithKline Vaccines Wavre Belgium

National Reference Laboratory for Streptococci and Enterococci National Institute of Public Health Prague Czech Republic

NRL for Haemophilus Infections National Institute of Public Health Prague Czech Republic

WHO Collaborating Center for Streptococci National Institute of Public Health Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc12027145

003      

CZ-PrNML

005      

20160426140240.0

007      

ta

008      

120816s2011 ne f 000 0#eng||

009      

AR

024    7_

$a 10.1016/j.vaccine.2010.12.086 $2 doi

035    __

$a (PubMed)21215830

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Prymula, Roman, $d 1964- $7 nlk19990073741 $u Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic. prymula@pmfhk.cz

245    10

$a Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage / $c R. Prymula, I. Hanovcova, M. Splino, P. Kriz, J. Motlova, V. Lebedova, P. Lommel, E. Kaliskova, T. Pascal, D. Borys, L. Schuerman

520    9_

$a Pneumococcal conjugate vaccines (PCV) may reduce nasopharyngeal carriage (NPC) of Streptococcus pneumoniae vaccine strains (VT), but serotype replacement with non-vaccine strains (NVT) has been reported. Bacterial NPC after PHiD-CV vaccination was assessed in the second year of life. Open descriptive study of NPC reported for 414 subjects vaccinated at 3-5 and 12-15 months of age with PHiD-CV with or without prophylactic paracetamol (PP) compared to 336 age-matched PCV-naïve controls. Carriage was assessed prior to and 1, 3, 7 and 12 months after PHiD-CV booster or MenACWY-TT control vaccination at 12-15 months of age. At each visit, carriage of VT was reduced by 22-35% in PHiD-CV recipients. Vaccine efficacy across all visits was 21.7% [95% CI 2.6; 37.0] (26.8% carriage in the PHiD-CV group versus 34.2% in controls). Carriage rates of NVT tended to be higher in PHiD-CV recipients. Pre-booster, these findings were more pronounced when PP had not been administered. No substantial effect of PHiD-CV vaccination was observed on NPC of other bacterial pathogens including non-typeable Haemophilus influenzae. Primary and booster vaccination with PHiD-CV reduced NPC of VT in the second year of life and tended to slightly increase that of NVT in line with previous experience with the 7-valent PCV.

650    _2

$a přenašečství $x prevence a kontrola $7 D002353

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a hemofilové infekce $x prevence a kontrola $7 D006192

650    _2

$a Haemophilus influenzae $x izolace a purifikace $7 D006193

650    _2

$a lidé $7 D006801

650    _2

$a sekundární imunizace $x metody $7 D007117

650    _2

$a kojenec $7 D007223

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a nazofarynx $x mikrobiologie $7 D009305

650    _2

$a pneumokokové infekce $x prevence a kontrola $7 D011008

650    _2

$a pneumokokové vakcíny $x aplikace a dávkování $x imunologie $7 D022242

650    _2

$a Streptococcus pneumoniae $x izolace a purifikace $7 D013296

650    _2

$a vakcinace $x metody $7 D014611

655    _2

$a časopisecké články $7 D016428

700    1_

$a Hanovcová, Irena $u Charles University in Prague, Faculty of Medicine in Hradec Kralove, Department of Clinical Microbiology, Hradec Kralove, Czech Republic $7 xx0064296

700    1_

$a Špliňo, Miroslav, $u Department of Epidemiology, Military Medical Academy, Hradec Kralove, Czech Republic $d 1940-2021 $7 jn20001103335

700    1_

$a Křížová, Pavla $u WHO Collaborating Center for Streptococci, National Institute of Public Health, Prague, Czech Republic $7 xx0048673

700    1_

$a Motlová, Jitka $u National Reference Laboratory for Streptococci and Enterococci, National Institute of Public Health, Prague, Czech Republic $7 xx0060345

700    1_

$a Lebedová, Věra $u NRL for Haemophilus Infections, National Institute of Public Health, Prague, Czech Republic $7 xx0062565

700    1_

$a Lommel, Patricia $u NRL for Haemophilus Infections, National Institute of Public Health, Prague, Czech Republic

700    1_

$a Kaliskova, Eva $u WHO Collaborating Center for Streptococci, National Institute of Public Health, Prague, Czech Republic

700    1_

$a Pascal, Thierry $u Global Vaccine Development, GlaxoSmithKline Vaccines, Wavre, Belgium

700    1_

$a Borys, Dorota $u Global Vaccine Development, GlaxoSmithKline Vaccines, Wavre, Belgium

700    1_

$a Schuerman, Lode $u Global Vaccine Development, GlaxoSmithKline Vaccines, Wavre, Belgium

773    0_

$w MED00004631 $t Vaccine $x 1873-2518 $g Roč. 29, č. 10 (2011), s. 1959-1967

856    41

$u https://pubmed.ncbi.nlm.nih.gov/21215830 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y m $z 0

990    __

$a 20120816 $b ABA008

991    __

$a 20160426140006 $b ABA008

999    __

$a ok $b bmc $g 949187 $s 784491

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2011 $b 29 $c 10 $d 1959-1967 $e 20110106 $i 1873-2518 $m Vaccine $n Vaccine $x MED00004631

LZP    __

$b NLK112 $a Pubmed-20120816/11/02